Loading market dashboard
Olin Corporation
OLNBasic MaterialsNYSEUS
Loading disclosure news
News and disclosures filtered by period, publisher, and event group.
Select a headline to open the full news page in the app.
On June 04, 2026, Olin Corp (OLN) shares fell 3.2% today, currently trading at $24.93. This price movement is particularly notable given the stock's 52-week ran
On May 29, 2026, Olin Corp (OLN) shares fell 3.3% to a current price of $25.87, reflecting a broader trend as the stock has decreased 4.8% over the past month.
Olin NYSE: OLN executives said the company expects a sharp sequential improvement in second-quarter earnings as higher pricing, seasonal demand and cost reductions begin to flow through results following a challenging but improving first quarter.
OLN beat Q1 loss estimates and topped sales forecasts as Winchester growth offset weaker Chemicals demand and margin pressure.
Olin Corporation (OLN) Q1 2026 Earnings Call Transcript
Olin (OLN) came out with a quarterly loss of $0.65 per share versus the Zacks Consensus Estimate of a loss of $0.67. This compares to earnings of $0.04 per share a year ago.
While the top- and bottom-line numbers for Olin (OLN) give a sense of how the business performed in the quarter ended March 2026, it could be worth looking at how some of its key metrics compare to Wall Street estimates and year-ago values.
Highlights First quarter 2026 net loss of ($83.0) million, or ($0.73) per diluted share Quarterly adjusted EBITDA of $86.2 million CLAYTON, Mo., May 7, 2026 /PRNewswire/ -- Olin Corporation (NYSE: OLN) announced financial results for the first quarter ended March 31, 2026.
Olin (OLN) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Olin is expected to implement one of its largest cost-saving goals this year, estimated to be between $100 and $120 million. Given that we are starting to see top line recovery, mainly driven by the epoxy segment, cost savings will bring margin expansion. Momentum, growth, and profitability metrics are improving well and are superior to its peers, but the valuation remains depressed with an upside potential of 68% in case of a re-rating.
Olin remains a buy as Middle East conflict tightens global petrochemical supply, supporting US-centric producers and improving pricing power. OLN's Q1 likely marks the bottom, with Q2 expected to benefit from lower US natural gas prices and improved margins, especially in Chlor Alkali. Despite weak construction demand, supply disruptions and cost tailwinds should drive at least $150M free cash flow in 2026, with further upside possible.
CLAYTON, Mo., April 2, 2026 /PRNewswire/ -- Olin Corporation (NYSE: OLN) announced today that on Friday, May 8, 2026, at 9:00 a.m.
OLN324 demonstrated meaningfully faster and greater improvements in anatomic outcomes in DME and numerically greater vision gains sustained through 20 weeks with fewer retreatments as compared to faricimab New anatomic data demonstrates OLN324 achieves faster, greater, and more durable reductions in wAMD pigment epithelial detachment (PED) thickness versus faricimab Ollin and Innovent Biologics adva ncing OLN324 into global Phase 3 studies in DME and wAMD in 2026 SAN FRANCISCO and SUZHOU, China, March 30, 2026 /PRNewswire/ -- Innovent Biologics, Inc. ("Innovent") (HKEX: 01801), a world-class biopharmaceutical company that develops, manufactures, and commercializes high-quality medicines for the treatment of oncology, autoimmune, cardiovascular and metabolic, ophthalmology and other major disease areas, today announced that the company's partner Ollin reported final, 20-week study completion data from its randomized, head-to-head Phase 1b JADE clinical study comparing OLN324(Innovent R&D code IBI324) , a higher-potency, smaller-format, higher-molar dose VEGF/Ang2 bispecific antibody, to faricimab (Vabysmo®), in patients with diabetic macular edema (DME) or wet (neovascular) age-related macular degeneration (wAMD). Final results released include favorable durability data for OLN324 compared to faricimab and new anatomic data showing faster, greater, and more durable control of wAMD pigment epithelial detachments (PEDs) with OLN324.
SG Americas Securities LLC raised its position in Olin Corporation (NYSE: OLN) by 142.0% in the undefined quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The institutional investor owned 455,757 shares of the specialty chemicals company's stock after acquiring an additional 267,458 shares during the quarter.
